



# Marksans Pharma Ltd.

Date: 4<sup>th</sup> February, 2023

**BSE Limited**  
Corporate Relation Department  
PhirozeJeejeeboi Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 524404

**National Stock Exchange of India Limited**  
Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400051.  
Symbol: MARKSANS

**Subject: Intimation of schedule of Earnings Conference Call**

Re : Marksans Pharma Limited (the Company) : Scrip Code-524404

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Company has scheduled a conference call for analysts and investors on Tuesday, February 14, 2023 at 5:00 P.M. (IST) on the Unaudited (standalone and consolidated) financial results of the Company for the quarter and nine month ended December 31, 2022.

Attached please find the conference call details as an Annexure.

You are requested to note the above in your records.

Thanking you.

Yours faithfully,  
**For Marksans Pharma Limited**

Harshavardhan Panigrahi  
**Company Secretary**

CIN : L24110MH1992PLC066364

[www.marksanspharma.com](http://www.marksanspharma.com)

**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011  
E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)



TM

SYSTEMATIX INSTITUTIONAL EQUITIES

## SYSTEMATIX INSTITUTIONAL EQUITIES

Invites you to participate in  
**3QFY23 Results Conference Call of**



### Marksans Pharma Ltd.

**On Tuesday, 14<sup>th</sup> February 2023 at 05.00 PM (IST)**

The management will be represented by

<b>Mr. Mark Saldanha</b> <i>Founder, Chairman, and Managing Director</i>	<b>Mr. Jitendra Sharma</b> <i>Chief Financial Officer</i>
---	--

Marksans Pharma is a generic drug formulation manufacturing company focused on the Private label OTC category products in regulated markets like the US and UK.. The company has delivered 12% compounded net earnings growth over the last 10 years and continues to generate healthy ROCE despite the inflationary environment and pricing pressures in regulated markets.

Dial-in-number

**Please join us on Zoom Meeting**

<https://us06web.zoom.us/j/84436356705?pwd=aUxuZ25vaE12TFBUNlpyYnFaeStFZz09>

<b>Meeting ID</b>	<b>844 3635 6705</b>
<b>Passcode</b>	<b>139708</b>

For more information, please contact:

**Vishal Manchanda**  
Contact No: +91 97374 37148  
[vishalmanchanda@systematixgroup.in](mailto:vishalmanchanda@systematixgroup.in)

**Pearl Pillay**  
Contact No: +91 91674 66762  
[pearlpillay@systematixgroup.in](mailto:pearlpillay@systematixgroup.in)